Cargando…

A nomogram for predicting the rapid progression of diffuse large B‐cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations

OBJECTIVES: This study aimed to integrate positron emission tomography/computed tomography (PET/CT) metrics and genetic mutations to optimize the risk stratification for diffuse large B‐cell lymphoma (DLBCL) patients. METHODS: The data of 94 primary DLBCL patients with baseline PET/CT examination co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Cong, Shi, Pengyue, Li, Zhenjiang, Li, Baosheng, Li, Zengjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501242/ https://www.ncbi.nlm.nih.gov/pubmed/37366281 http://dx.doi.org/10.1002/cam4.6295

Ejemplares similares

Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
por: Voropaeva, Elena N., et al.
Publicado: (2019)

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma
por: Fang, Ying, et al.
Publicado: (2023)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
por: He, Sanxiu, et al.
Publicado: (2023)

Baseline (18)F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma
por: Jing, Fenglian, et al.
Publicado: (2023)

Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma
por: Aide, Nicolas, et al.
Publicado: (2017)

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma
por: Tang, Jing, et al.
Publicado: (2023)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma
por: Ilyas, Hajira, et al.
Publicado: (2018)

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
por: Cao, Yang, et al.
Publicado: (2016)

P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS
por: Uppal, Manik, et al.
Publicado: (2023)

α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis
por: Cai, Yiqing, et al.
Publicado: (2023)

Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review
por: Frood, R., et al.
Publicado: (2021)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

Development and validation of a [(18)F]FDG PET/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients
por: Li, Mingshan, et al.
Publicado: (2022)

Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell Lymphoma: Is There a Superior Method?
por: Eude, Florian, et al.
Publicado: (2021)

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion
por: Sinkoff, Jillian, et al.
Publicado: (2017)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Prognostic Value of Baseline Radiomic Features of (18)F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma
por: Lue, Kun-Han, et al.
Publicado: (2020)

Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
por: Asmar, Fazila, et al.
Publicado: (2014)

Correlations between baseline (18)F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma
por: Decazes, Pierre, et al.
Publicado: (2020)

Correlations between Functional Imaging Markers Derived from PET/CT and Diffusion-Weighted MRI in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
por: Wu, Xingchen, et al.
Publicado: (2014)

(18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2021)

Prognostic parameters on baseline and interim [(18)F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients
por: Czibor, Sándor, et al.
Publicado: (2023)

Evaluation of the Effects of R-CHOP Chemotherapy on Brain Glucose Metabolism in Patients with Diffuse Large B Cell Lymphoma: A Baseline, Interim, and End-of-Treatment PET/CT Study
por: Zhu, Haiyan, et al.
Publicado: (2022)

Prognostic value of baseline total metabolic tumour volume of (18)F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2021)

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
por: Maschietto, Mariana, et al.
Publicado: (2014)

Predictive value of baseline (18)F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy
por: Zhu, Lili, et al.
Publicado: (2021)

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis
por: Dobashi, Akito, et al.
Publicado: (2018)

Detection of Diffuse Infiltrative Primary Hepatic Lymphoma on FDG PET-CT: Hallmarks of Hepatic Superscan
por: Mahajan, Sonia, et al.
Publicado: (2016)

Primary Pulmonary Diffuse Large B-Cell Lymphoma on FDG PET/CT-MRI and DWI
por: Xu, Huiting, et al.
Publicado: (2015)

Gallbladder Involvement of Diffuse Large B-Cell Lymphoma with (18)F-FDG PET/CT
por: Arslan, Esra, et al.
Publicado: (2022)

Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma
por: Liang, Jin-Hua, et al.
Publicado: (2016)

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma
por: Li, Xiaoqian, et al.
Publicado: (2019)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

PB2378: COMPREHENSIVE ANALYSIS OF P53-RESPONSIVE MIRNA’S GENES METHYLATION, TP53 GENE MUTATIONS AND POLYADENYLATION SIGNAL DESTRUCTION IN DIFFUSE LARGE B-CELL LYMPHOMA TUMOR TISSUE.
por: Voropaeva, Elena, et al.
Publicado: (2023)

Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy
por: Zhang, Xu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_negumjapt8gl6qr64ps0q7hadr